KROS - Keros climbs as Piper Sandler cheers mid-stage KER-050 data in myelodysplastic Syndromes

Keros Therapeutics (KROS +26.1%) has reached a four-month high after the company highlighted an abstract posted on the website of the American Society of Hematology (“ASH”) indicating data from a Phase 2 trial for its lead protein candidate KER-050 in myelodysplastic Syndromes (MDS). In the open-label trial, among 17 subjects who received KER-050 at three dose levels, the treatment was well tolerated with no dose-limiting toxicities at the data cutoff of July 10. Two had discontinued the drug before the completion of treatment. There was one mortality that was found to be unrelated to the drug. “These data support the potential of KER-050 as a treatment for multilineage cytopenias in MDS by potentially targeting multiple stages of hematopoiesis,” the authors wrote. “Erythroid responses have been observed in RS+ and non-RS MDS patients, including a reduction in transfusion burden at the initial dose levels,” they noted, pointing to the MDS patients categorized by the

For further details see:

Keros climbs as Piper Sandler cheers mid-stage KER-050 data in myelodysplastic Syndromes